Table 1 Cohort characteristics
Cohort | All (n = 51) | Analytical cohort (n = 43) |
|---|---|---|
Characteristic | ||
Age at diagnosis – median [range] | 52.8 [36.5–81.7] | 52.8 [36.5–81.7] |
Age at study entry – median [range] | 59.4 [38.1–88.2] | 63.4 [38.1–88.2] |
Age at study entry – no. (%) | ||
<40 | 1 (2) | 1 (2) |
40–50 | 6 (12) | 5 (12) |
50–60 | 18 (35) | 11 (26) |
>60 | 26 (51) | 26 (60) |
Sex – no. (%) | ||
Female | 50 (98) | 43 (100) |
Male | 1 (2) | 0 (0) |
Premenopausal – no. (%) | 10 (20) | 8 (19) |
De novo metastatic – no. (%) | 16 (31) | 11 (26) |
Disease sites – no. (%) | ||
Visceral | 34 (67) | 28 (65) |
Bone-only | 10 (20) | 8 (19) |
Line of therapy – no. (%) | ||
First | 40 (78) | 34 (79) |
Second | 9 (18) | 8 (19) |
Third or above | 2 (4) | 1 (2) |
CDK4/6 inhibitor – no. (%) | ||
Palbociclib | 38 (74) | 34 (79) |
Ribociclib | 11 (22) | 8 (19) |
Abemaciclib | 2 (4) | 1 (2) |
Endocrine therapy pair – no. (%) | ||
Aromatase inhibitor | 34 (67) | 27 (63) |
SERD | 16 (31) | 15 (35) |
SERM | 1 (2) | 1 (2) |
